Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Fig. 3

Kaplan-Meier curves of overall survival in ESCC patients in relation to SLFN11 expression. a In all subjects, prognosis after dCRT of the high SLFN11 group was significantly better than that of the low SLFN11 group (p = 0.013). b In clinical stage I (cT1b) patients, SLFN11-dependent differences in overall survival were not observed (p = 0.564). However, in clinical stage II + III (c) and clinical stage IVA + IVB (cM1-lym) patients (d), prognosis of the high SLFN11 group was better than that of the low SLFN11 group (p = 0.004 and p = 0.007, respectively). Abbreviations: ESCC, esophageal squamous cell carcinoma; dCRT, definitive chemoradiotherapy; clinical stage, clinical stage in UICC 8th edition; cT1b, tumor invasion to the submucosa; cM1-lym, distant lymph node metastasis

Back to article page
\